venlafaxine hydrochloride has been researched along with Depressive Disorder, Treatment-Resistant in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 32 (88.89) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Hein, M; Mungo, A | 1 |
| Eggleston, K; Porter, RJ | 1 |
| Blumberger, DM; Buchalter, ELF; Dixon, D; Karp, JF; Lenze, EJ; Miller, JP; Mulsant, BH; Oughli, HA; Reynolds, CF | 1 |
| Gruca, P; Lason, M; Litwa, E; Papp, M; Solecki, W; Willner, P | 1 |
| Kamphuis, J; Schlegel, M; Schoevers, RA; Veraart, JKE | 1 |
| Khanam, R; Thomas, J; Vohora, D | 1 |
| Broadhouse, K; Gordon, E; Grieve, SM; Koslow, S; Maller, JJ; Rush, AJ | 1 |
| Dold, M; Kasper, S; Mendlewicz, J; Montgomery, S; Olgiati, P; Serretti, A; Souery, D; Zohar, J | 1 |
| Gruca, P; Lason, M; Litwa, E; Niemczyk, M; Papp, M; Tota-Glowczyk, K; Willner, P | 2 |
| Gruca, P; Lason, M; Niemczyk, M; Papp, M; Willner, P | 1 |
| Kasper, S; Kraus, C; Mendlewicz, J; Montgomery, S; Olgiati, P; Serretti, A; Souery, D; Zohar, J | 1 |
| Bajbouj, M; Cooper, K; Daly, EJ; Drevets, WC; Hough, D; Lane, R; Lim, P; Manji, H; Mazzucco, C; Molero, P; Popova, V; Shelton, RC; Singh, JB; Thase, ME; Trivedi, M; Vieta, E | 1 |
| Ameele, HVD; Blier, P; Daly, EJ; Drevets, WC; Fava, M; Fedgchin, M; Gaillard, R; Hough, D; Lane, R; Liebowitz, M; Lim, P; Manji, H; Melkote, R; Preskorn, S; Ravindran, A; Singh, JB; Trivedi, M; Vitagliano, D | 1 |
| Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, R; Keller, MB; Mansoor, BM; Mayes, T; Porta, G; Rengasamy, M; Ryan, ND; Shamseddeen, W; Wagner, KD | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, GN; Emslie, GJ; He, J; Hilton, RC; Keller, MB; Mansoor, B; Mayes, T; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Wagner, KD | 1 |
| Birmaher, B; Brent, D; Clarke, G; Emslie, GJ; He, J; Hilton, R; Mansoor, B; Mayes, TL; Porta, G; Rengasamy, M; Ryan, N; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
| Ellis, N; Garcia, A; Nakama, H; O'Brien, K | 1 |
| Ait Tayeb, AEK; Becquemont, L; Corruble, E; Dutech, C; Ellul, P; Gressier, F; Hardy, P; Monfort, J; Verstuyft, C | 1 |
| Calati, R; Dikeos, D; Gailledreau, J; Juven-Wetzler, A; Kasper, S; Mendlewicz, J; Modavi, D; Montgomery, S; Papadimitriou, GN; Papageorgiou, K; Pitchot, W; Sentissi, O; Serretti, A; Souery, D; Zohar, J | 1 |
| Balestri, M; Calati, R; Kasper, S; Kautzky, A; Mendlewicz, J; Montgomery, S; Serretti, A; Souery, D; Zohar, J | 1 |
| Diaz, SH; Dunklee, L; Escalona, R; Fawcett, J; Romo, P; Rush, AJ; Vukelich, J; Yarns, BC | 1 |
| Berger, M; Braus, DF; Dahmen, N; Dreimüller, N; Engel, A; Gorbulev, S; Helmreich, I; Hiemke, C; Kaiser, AK; Kronfeld, K; Lieb, K; Schlicht, KF; Tadić, A; Tüscher, O; van Calker, D; Wachtlin, D; Wagner, S | 1 |
| Aizenstein, HJ; Anderson, SJ; Blumberger, D; Butters, MA; Dew, MA; Diniz, BS; Kaneriya, SH; Karp, JF; Lenze, EJ; Lotrich, F; Mulsant, BH; Reynolds, CF; Robbins-Welty, GA; Smagula, SF | 1 |
| Gordon, E; Grieve, SM; Korgaonkar, MS; Rush, AJ; Williams, LM | 1 |
| Blumberger, D; Butters, M; Buysse, DJ; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, B; Reynolds, CF; Stahl, ST; Waterman, L | 1 |
| Brand, SJ; Harvey, BH | 1 |
| Brunelin, J; Haesebaert, F; Moirand, R; Poulet, E; Schott-Pethelaz, AM | 1 |
| Albani, D; Calabrò, M; Calati, R; Crisafulli, C; Fabbri, C; Forloni, G; Juven-Wetzler, A; Kasper, S; Martines, R; Mendlewicz, J; Montgomery, S; Serretti, A; Souery, D; Zohar, J | 1 |
| Bostic, JQ | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, G; Keller, MB; Mayes, T; Porta, G; Ryan, ND; Shamseddeen, W; Wagner, KD | 1 |
| Dusetzina, SB; Ellis, AR; Farley, JF; Gaynes, BN; Hansen, RA; Miller, WC; Stürmer, T | 1 |
| Weder, N | 1 |
| Rubin, DH | 1 |
| Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Dickerson, JF; Dietz, LJ; Emslie, G; Keller, M; Kennard, B; Lynch, FL; Mayes, T; McMakin, DL; Olino, TM; Porta, G; Ryan, ND; Shamseddeen, W; Spirito, A; Wagner, KD | 1 |
2 review(s) available for venlafaxine hydrochloride and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
[The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature].
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Duloxetine Hydrochloride; Humans; Middle Aged; Randomized Controlled Trials as Topic; Serotonin and Noradrenaline Reuptake Inhibitors; Venlafaxine Hydrochloride; Young Adult | 2022 |
Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Prognosis; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride | 2018 |
16 trial(s) available for venlafaxine hydrochloride and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Predicting Remission in Late-Life Major Depression: A Clinical Algorithm Based Upon Past Treatment History.
Topics: Algorithms; Antidepressive Agents; Anxiety Disorders; Aripiprazole; Clinical Decision Rules; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Humans; Likelihood Functions; Prospective Studies; Recurrence; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression.
Topics: Adult; Age Factors; Antidepressive Agents; Citalopram; Cohort Studies; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Hippocampus; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Organ Size; Pattern Recognition, Automated; Prognosis; Psychiatric Status Rating Scales; Remission Induction; Sertraline; Venlafaxine Hydrochloride | 2018 |
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Topics: Administration, Intranasal; Administration, Oral; Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride | 2019 |
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
Topics: Administration, Intranasal; Administration, Oral; Adolescent; Adult; Antidepressive Agents; Citalopram; Delayed-Action Preparations; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Ketamine; Male; Middle Aged; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2019 |
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2013 |
The bi-directional relationship between parent-child conflict and treatment outcome in treatment-resistant adolescent depression.
Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Conflict, Psychological; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Parent-Child Relations; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.
Topics: Adolescent; Anxiety; Attention Deficit and Disruptive Behavior Disorders; Behavioral Symptoms; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Body Mass Index; Child; Citalopram; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2013 |
Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prospective Studies; Retrospective Studies; Risk Factors; Severity of Illness Index; Socioeconomic Factors; Venlafaxine Hydrochloride; Young Adult | 2016 |
Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Delayed-Action Preparations; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Early Medical Intervention; Female; Humans; Lithium; Male; Middle Aged; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult | 2016 |
Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Anxiety; Aripiprazole; Comorbidity; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Executive Function; Female; Follow-Up Studies; Humans; Male; Middle Aged; Odds Ratio; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Set, Psychology; Severity of Illness Index; Treatment Failure; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Prediction of nonremission to antidepressant therapy using diffusion tensor imaging.
Topics: Adult; Antidepressive Agents; Brain; Citalopram; Delayed-Action Preparations; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nerve Net; Predictive Value of Tests; Psychiatric Status Rating Scales; Sertraline; Venlafaxine Hydrochloride; White Matter; Young Adult | 2016 |
Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Databases, Genetic; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Neuronal Plasticity; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Remission Induction; Second Messenger Systems; Treatment Outcome; Venlafaxine Hydrochloride | 2017 |
Treatment-resistant depressed youth show a higher response rate if treatment ends during summer school break.
Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Social Adjustment; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2011 |
Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Buspirone; Citalopram; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Humans; Likelihood Functions; Male; Middle Aged; Personality Inventory; Psychometrics; Quality of Life; Sertraline; United States; Venlafaxine Hydrochloride; Young Adult | 2012 |
Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression.
Topics: Adolescent; Affect; Anhedonia; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Resistance; Drug Substitution; Female; Humans; Longitudinal Studies; Male; Personality Assessment; Psychometrics; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
18 other study(ies) available for venlafaxine hydrochloride and Depressive Disorder, Treatment-Resistant
| Article | Year |
|---|---|
Neurocognitive Effects of Electroconvulsive Therapy-What Do Patients and Clinicians Need to Know?
Topics: Aged; Depression; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Humans; Venlafaxine Hydrochloride | 2020 |
AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar-Kyoto rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Deep Brain Stimulation; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Excitatory Amino Acid Agents; Hippocampus; Male; Optogenetics; Prefrontal Cortex; Rats; Rats, Inbred WKY; Rats, Wistar; Receptors, AMPA; Stress, Psychological; Venlafaxine Hydrochloride | 2020 |
Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities.
Topics: Administration, Oral; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Clozapine; Deep Brain Stimulation; Depressive Disorder, Treatment-Resistant; Electroconvulsive Therapy; Female; Glycopyrrolate; Hallucinations; Humans; Ketamine; Middle Aged; Muscarinic Antagonists; Nitrazepam; Obsessive-Compulsive Disorder; Treatment Failure; Venlafaxine Hydrochloride | 2021 |
Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Depression; Depressive Disorder, Treatment-Resistant; Female; Hippocampus; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Interleukin-1beta; Interleukin-6; Kynurenine; Male; Mice; Olanzapine; Serotonin; Stress, Psychological; Swimming; Tryptophan; Venlafaxine Hydrochloride | 2017 |
Rapid antidepressant effects of deep brain stimulation of the pre-frontal cortex in an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Deep Brain Stimulation; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Imipramine; Male; Prefrontal Cortex; Rats; Rats, Wistar; Stress, Psychological; Venlafaxine Hydrochloride | 2018 |
Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Citalopram; Depression; Depressive Disorder; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Imipramine; Ketamine; Male; Prefrontal Cortex; Rats; Rats, Inbred WKY; Rats, Wistar; Stress, Psychological; Venlafaxine Hydrochloride | 2019 |
The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression.
Topics: Animals; Behavior, Animal; Deep Brain Stimulation; Depression; Depressive Disorder, Treatment-Resistant; Dopamine; Dopamine Agonists; Dopamine Antagonists; Male; Memory Consolidation; Models, Animal; Prefrontal Cortex; Rats; Rats, Inbred WKY; Rats, Wistar; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydronaphthalenes; Venlafaxine Hydrochloride | 2019 |
Attrition in treatment-resistant depression: predictors and clinical impact.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Patient Dropouts; Venlafaxine Hydrochloride | 2019 |
Case report of a 24-year-old man with resolution of treatment-resistant major depressive disorder and comorbid PTSD using rTMS.
Topics: Antidepressive Agents, Second-Generation; Combat Disorders; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Diagnostic and Statistical Manual of Mental Disorders; Humans; Male; Military Personnel; Stress Disorders, Post-Traumatic; Transcranial Magnetic Stimulation; Venlafaxine Hydrochloride; Young Adult | 2014 |
Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.
Topics: Cyclohexanols; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Depressive Disorder, Treatment-Resistant; Genotype; Humans; Male; Middle Aged; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Venlafaxine Hydrochloride | 2014 |
What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Prospective Studies; Psychiatric Status Rating Scales; Serotonin and Noradrenaline Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride | 2015 |
Clinical Experience With High-Dosage Pramipexole in Patients With Treatment-Resistant Depressive Episodes in Unipolar and Bipolar Depression.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Benzothiazoles; Bipolar Disorder; Bupropion; Cohort Studies; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nortriptyline; Pramipexole; Retrospective Studies; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Self-reported obstructive sleep apnea is associated with nonresponse to antidepressant pharmacotherapy in late-life depression.
Topics: Aged; Antidepressive Agents, Second-Generation; Canada; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Geriatric Assessment; Humans; Male; Missouri; Pennsylvania; Self Report; Sleep Apnea, Obstructive; Treatment Outcome; Venlafaxine Hydrochloride | 2016 |
Exploring a post-traumatic stress disorder paradigm in Flinders sensitive line rats to model treatment-resistant depression II: response to antidepressant augmentation strategies.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Cerebral Cortex; Depressive Disorder, Treatment-Resistant; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipramine; Ketamine; Male; Rats; Rats, Transgenic; Stress Disorders, Post-Traumatic; Venlafaxine Hydrochloride | 2017 |
Usefulness of repetitive transcranial magnetic stimulation as a maintenance treatment in patients with major depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Transcranial Magnetic Stimulation; Venlafaxine Hydrochloride | 2018 |
Summer is the best time for Treatment of Resistant Depression in Adolescents (TORDIA): the importance of school in medication trials.
Topics: Cognitive Behavioral Therapy; Cyclohexanols; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2011 |
Saving lives: can we predict and prevent adolescent suicide?
Topics: Anhedonia; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |
Joy returns last: anhedonia and treatment resistance in depressed adolescents.
Topics: Anhedonia; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride | 2012 |